Response to R. Waldman, M.E. DeWane, S. Brett Sloane: "Letter in Reply - Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?"
Response to R. Waldman, M.E. DeWane, S. Brett Sloane: "Letter in Reply - Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?"
Br J Dermatol. 2019 Dec 18;:
Authors: Ardeleanu M, Shumel B, Rossi AB, Graham NMH
Abstract
Bakker et al. proposed that interleukin (IL)-13 inhibition-induced goblet cell decline drives dupilumab-associated conjunctivitis in atopic dermatitis (AD).1 In response, Waldman et al.2 suggested that IL-4 inhibition is essential, citing TREBLE, a randomized, 12-week, placebo-controlled, dose-ranging phase 2 trial of lebrikizumab (anti-IL-13 monoclonal antibody) in moderate-to-severe AD.
PMID: 31853960 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Ardeleanu M, Shumel B, Rossi AB, Graham NMH Tags: Br J Dermatol Source Type: research